See the Sun in a Way You've Never Seen It Before, From Above and Below
Every image you've ever seen of the sun is looking at its equator, because Earth's orbit sits there with a 7.25-degree tilt. That means humans have never had a good angle to view the sun's north and south poles until now. The ESA has released images of the sun's north and south poles, giving everyone their first glimpse at the top and bottom of our nearest star.
The imagery was taken by the ESA's Solar Orbiter, which began its trek to view the sun's polar regions in 2020. To do this, the Orbiter engaged its boosters, made some adjustments and slingshotted itself around Venus at a staggering 27,000 MPH.
Once it reached its destination, it took images using its Polarimetric and Helioseismic Imager (PHI), the Extreme Ultraviolet Imager (EUI), and the Spectra Imaging of the Coronal Environment (SPICE) instrument.
"Today we reveal humankind's first-ever views of the sun's poles," said Professor Carole Mundell, ESA Director of Science, in a blog post. "The sun is our nearest star, giver of life and potential disruptor of modern space and ground power systems, so it is imperative that we understand how it works and learn to predict its behaviour. These new unique views from our Solar Orbiter mission are the beginning of a new era of solar science."
See the Solar Orbiter's stunning sun view
The sun's poles.
ESA
The images are viewable above or in a YouTube video on ESA's channels. In the video, you can see the view that we Earthlings generally see before the video transitions to the solar orbiter's viewpoint and zooms in so you can see the bottom of the sun in all of its hot, fiery glory. The video is only 50 seconds, but it's 50 seconds of footage that humans have never seen before.
Most of the ESA's images and videos are of the sun's South Pole, but the blog post includes imagery of the North Pole as well. For the most part, scientists had no idea what to expect from the data, given that this is the first time any human had seen it before.
The full dataset from the Orbiter's first pole-to-pole adventure is set to reach Earth by October 2025, which will give scientists much more to work with in terms of understanding how the sun works. Future orbits will include measurements from all 10 of the Orbiter's tools, so even more information is coming over the next few years.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
27 minutes ago
- Medscape
Immune Modulation in MDS: Our Core Strategies Need to Change
MILAN — Immune-based treatments continue to fall short in myelodysplastic syndromes (MDS). Now, experts from the European Hematology Association's (EHA) Specialized Working Group on MDS here at the EHA 2025 Congress are reevaluating their core strategies, from clinical trial endpoints to patient selection and timing. The researchers are suggesting the need for a shift in how these therapies are developed and deployed, as new data suggests that current benchmarks might be missing meaningful responses and that immune dysfunction in MDS can evolve over time. MDS are a heterogeneous group of clonal myeloid stem and progenitor cell disorders marked by ineffective hematopoiesis, cytopenias, and a risk of progression to acute myeloid leukemia. Immune dysregulation is thought to be a key driver in MDS pathogenesis, raising hopes that modulating immune responses within the bone marrow niche could alter disease trajectory. Yet, despite numerous attempts, immune-based interventions have largely failed to yield meaningful clinical results. Choosing the Right Endpoints Currently, few therapies targeting inflammation and immune activation are approved for MDS — namely antithymocyte globulin, with or without cyclosporine A, lenalidomide, and luspatercept. However, a growing list of investigational agents is under study, including cytokine inhibitors, signaling pathway inhibitors, immune checkpoint inhibitors, bispecific and trispecific antibodies, and chimeric antigen receptor cell-based therapies. Anne Sophie Kubasch, MD Anne Sophie Kubasch, MD, a hematologist at the University Medical Hospital Leipzig, Germany, presented preliminary findings from two trials by the German MDS Study Group: the phase 2 CANFIRE trial of the IL-1Beta inhibitor canakinumab and the LUCAS trial of the IRAK4 inhibitor emavusertib. The CANFIRE trial enrolled 11 patients treated for 6 months, while LUCAS included 36 patients treated for 4 months. Both studies failed to meet their primary endpoint, hematologic improvement in erythroid cells per International Working Group (IWG) 2018 criteria, by the end of the treatment period. Despite this, Kubasch noted that several patients opted to continue treatment due to perceived clinical benefit, such as reduced fatigue or general improvement. Some also showed biomarker changes or delayed hematologic responses. These findings led her to question whether hematologic improvement in erythroid cells is the most appropriate efficacy endpoint for immunomodulatory agents. 'We can argue that current IWG endpoint criteria are too rigid for immune modulation trials,' she said. 'Late or gradual responses may go undetected.' Kubasch suggested that future trials should incorporate patient-reported outcomes and quality-of-life metrics as co-primary endpoints. 'We may focus on composite endpoints combining various parameters, such as hematologic trends, biomarker shifts, molecular remission or stability, and, of course, patient-reported benefits.' Selecting the Right Patients A second key question, Kubasch said, is whether the right patients are being selected for immunotherapy. She cited a recent transcriptomic analysis of bone marrow CD34+ cells from 183 MDS patients that identified two immune subtypes based on the expression of six genes — including IRAK4 , the target of emavusertib. These subtypes were called hyperactive (HIC) and moderate (MIC) immune clusters. The HIC group had greater activation of immune-related pathways and higher infiltration of natural killer cells and M1 macrophages. 'We might be treating the wrong immune subgroup with immunomodulators,' she said, hypothesizing that it's possible that only MIC patients were being enrolled in their trials, contributing to negative results. She proposed a stepwise stratification approach: Baseline assessment (low-risk MDS diagnosis, anemia, transfusion burden) Genetic stratification (cytogenetics, mutations, resistance markers) Immune transcriptomic profiling (HIC/MIC clustering) 'Selective inclusion of patients with immune activation, such as those with an HIC profile, is essential,' she concluded. Targeting the Right Immune Alterations Valeria Santini, MD, associate professor of hematology at the University of Florence Medical School, Italy, focused her remarks on immunosuppressive therapy, a long-used but inconsistently effective strategy in MDS. To re-evaluate its role, Santini reviewed older literature — what she called 'archaeological digging.' She showed that complete responses and survival benefits are achievable in some patients, albeit rarely. Importantly, she emphasized that immune dysfunction in MDS is dynamic. 'It changes during the course of the disease,' she said. Therefore, precise immune profiling at both the subtype and patient level is needed. Optimization of immunosuppressive therapy is hampered by the lack of prospective randomized trials, heterogeneity in study populations, poor characterization of immune abnormalities, and the need for integration with novel agents. 'It is not one cure for all,' she said. 'By selecting patients, we might be more successful than in the past.' Finding the Right Drugs and the Right Timing Lionel Adès, MD, PhD, professor of hematology at Saint-Louis Hospital, Paris, France, commented to Medscape Medical News that, while the biological rationale for immune modulation is strong, clinical evidence remains weak. Lionel Adès, MD, PhD 'Maybe we don't have the right drugs or combinations. Maybe we're using them too late in the disease course,' he said. Immune dysregulation might play a role early in MDS, but by the time patients are treated, it could be too late to alter the disease with immune-targeted agents. Moreover, Adès noted that immune therapies often require extended treatment periods before activity can be detected, while traditional MDS trial endpoints focus on earlier timepoints. 'If a drug appears completely ineffective, it's not ethical to keep a patient on trial for a year just to see if something happens,' he said. Still, he remains cautiously optimistic. He pointed to the EHA-sponsored i4MDS Consortium, which aims to deepen understanding of MDS immunobiology, and to data from the STIMULUS MDS 2 study presented during the session by Amer Zeidan, MBBS, MHS, of Yale University, New Haven, Connecticut. That study evaluated the TIM-3 immune checkpoint inhibitor sabatolimab plus azacitidine as a first-line therapy in MDS. Although the trial failed to show a survival advantage overall, subgroup analysis revealed a benefit among female patients. 'This is something very interesting,' Adès said. 'It's something we didn't look at before, because we never thought survival could differ between male and female MDS patients.' While sabatolimab development has since been discontinued, other agents targeting the same pathway remain in the pipeline. 'This finding could be valuable for stratifying future trials by sex,' he said. Kubasch reported relationships with BMS, Curis, Jazz, Johnson & Johnson, and Novartis. Santini reported serving on advisory boards for AbbVie, Ascentage, BMS, Geron, GSK, Keros, Novartis, Servier, and Takeda. Adès disclosed research support from BMS/Celgene and AbbVie, and advisory roles with AbbVie, Amgen, BMS, Jazz, Novartis, Roche, and Takeda.
Yahoo
44 minutes ago
- Yahoo
Bacteria will turn to murder if they get hungry enough
Bacteria operate by a pretty simple set of biological commands: survive and reproduce. But a recent study is highlighting that, in some cases, the microscopic organisms will follow those commands by any means necessary. Even if it entails killing and devouring their fellow bacteria. 'The punchline is: when things get tough, you eat your neighbors,' said Glen D'Souza, an Arizona State University molecular scientist and senior author of the paper published June 12 in the journal Science. D'Souza explained that while most bacteria absorb nutrients from the environment around them, it's 'textbook behavior' for certain species to kill each other. However, what he and colleagues observed was something different. In some instances, usually harmless bacteria will turn to violence if desperate. 'What we're seeing is that it's not just important that the bacteria have weapons to kill, but they are controlling when they use those weapons specifically for situations to eat others where they can't grow themselves,' D'Souza said. 'A microbial Jekyll and Hyde,' added Ferran Garcia-Pichel, ASU's director of Biodesign Center for Fundamental and Applied Microbiomics who was not involved in the study. D'Souza's team focused on a specific process inside bacteria called the Type VI Secretion System (T6SS). Similar to a tiny harpoon gun, T6SS enables bacteria to shoot a microscopic, needlelike weapon loaded with toxins into neighboring cells and organisms, causing them to fatally tear apart. Previously, microbiologists believed that bacteria mostly used their T6SS to eradicate rivals and make space for their own growth. But after utilizing timelapse imaging and other genetic analysis tools, the team recorded various bacteria using T6SS in a startling way. When nutrients were scarce, the organisms ambushed nearby bacteria and injected them with toxins. They then fed off of their targets as they essentially 'bled out.' 'By slowly releasing nutrients from their neighbors, they maximize their nutrient harvesting when every molecule counts,' said study first author Astrid Stubbusch. To prove that this behavior was, in fact, intentional, the team genetically switched off the T6SS in sample bacteria, and then placed them into a nutrient-starved setting. Those without the ability to use their mini-harpoons eventually died, but the unaltered bacteria began killing to survive.'This isn't just happening in the lab,' D'Souza clarified. 'It's present in many different environments and it's operational and happening in nature from the oceans to the human gut.' The ramifications go beyond microscopic horror stories. Understanding these systems allows researchers to gain a more complete picture of the microbial food chain and illustrate just how resourceful bacteria really are. It may also help pave the way for new antibiotics, or design drugs that harness T6SS to directly attack pathogens. The observations also have implications outside the human body. Many ocean bacteria are responsible for helping regulate Earth's carbon cycle. If some of them are using T6SS to devour bacteria that break down algae and recycle carbon, then ecologists can study how these influence planetary ecosystems. 'Watching these cells in action really drives home how resourceful bacteria can be,' added Stubbusch.
Medscape
5 hours ago
- Medscape
BMI & Nutrition Support Predict Weight Loss in Liver Disease
In patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), higher BMI, nutritionist support, and liver stiffness measurement ≥ 10 kPa were significant predictors of at least 7% weight reduction. METHODOLOGY: Researchers conducted a retrospective study to identify clinical factors that predict successful and sustained weight loss in 897 patients with MASLD (mean age, 61.6 years; 57.1% men; mean BMI, 30.3). They were referred between January 2019 and December 2021, with follow-up occurring between 18 and 24 months at four Italian tertiary centres. The diagnosis of MASLD was confirmed if patients had hepatic steatosis on ultrasound and at least one cardiometabolic risk factor, such as a BMI ≥ 25 or high waist circumference, fasting glucose levels ≥ 100 mg/dL or type 2 diabetes, blood pressure ≥ 130/85 mm Hg, triglyceride levels ≥ 150 mg/dL, or low levels of high-density lipoprotein cholesterol. Baseline and follow‐up data, including demographic, anthropometric, clinical, and biochemical parameters, as well as liver stiffness measurements, were collected from medical records. Details on lifestyle interventions such as Mediterranean diet recommendations, physical activity, and support from a nutritionist were also noted. TAKEAWAY: Over a median duration of 21 months, 18.3% of patients achieved at least 7% weight loss, with 8.5% losing 7%-10% and 9.8% losing more than 10% of their baseline weight. Higher baseline BMI was associated with increased odds of weight loss, with BMI 30-34.9 (adjusted odds ratio [aOR], 1.95; 95% CI, 1.30-2.95) and BMI ≥ 35 (aOR, 2.08; 95% CI, 1.21-3.57) associated with at least 7% weight loss. Nutritionist support (aOR, 2.04; 95% CI, 1.12-3.71), liver stiffness measurement ≥ 10 kPa (aOR, 1.70; 95% CI, 1.07-2.70), and bilirubin levels ≥ 1.2 mg/dL (aOR, 2.12; 95% CI, 1.29-3.51) were independent predictors of achieving at least 7% weight loss. The use of GLP-1 agonists was significantly associated with an increased likelihood of losing at least 7% weight (aOR, 1.85; 95% CI, 1.19-3.80). IN PRACTICE: "Our findings underscore the importance of a comprehensive approach to MASLD management, encompassing medical, nutritional and lifestyle interventions," the authors of the study wrote. "Lifestyle intervention remains crucial for all patients, but for those without predictive factors, close follow-up and early consideration of additional treatments are warranted to maximize therapeutic benefit," they added. SOURCE: This study was led by Nicola Pugliese, Humanitas University, Milan, Italy. It was published online on June 04, 2025, in United European Gastroenterology Journal . LIMITATIONS: This study was retrospective in nature with varying observation periods among the patients. A standardised intervention protocol was lacking across centres, potentially leading to varying management. The absence of systematic data collection from intermediate visits and self-reported data also presented a limitation. DISCLOSURES: This study was supported by funding from the Italian Ministry for Education, University and Research and other projects to an author. The authors reported having no conflicts of interest.
